bay94-9392

Small moleculeexperimentalImaging agent

Chemistry & pharmacology

Imaging
18-fluorine

Oral

No

Parenteral

No

Topical

No

Also known as

  • bay94-9392

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04488094Phase 2Nov 18, 2020University of Ulsan
NCT03824535Phase 2Feb 4, 2019Boston University, Canary Foundation, Stanford University
NCT03546868Phase 2Aug 14, 2018University of Ulsan
NCT03275974Early Phase 1 (Phase 1)Oct 17, 2017University of Texas at Houston
NCT02599194Phase 2Jul 1, 2015National Cancer Institute (NCI), Stanford University
NCT02448225Phase 2Jun 1, 2015National Cancer Institute (NCI), Vanderbilt University
NCT02379377N/AMar 1, 2015National Cancer Institute (NCI), Vanderbilt University
NCT01186601Phase 1Dec 1, 2010Bayer, Piramal
NCT01103310Phase 1Apr 1, 2010Bayer, Piramal
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government3022015
BayerFor profit2012010
PiramalFor profit2212010
Stanford UniversityAcademic/Hospital2212015
University of UlsanAcademic/Hospital2212018
Vanderbilt UniversityAcademic/Hospital2222015
Boston UniversityAcademic/Hospital1012019
Canary FoundationAcademic/Hospital1012019
University of Texas at HoustonAcademic/Hospital1112017
9 organizations
Page 1 / 1